Tracker

ETF universe handoff

Opening ETF evidence benchSynchronizing prices, risk metrics, holdings coverage, and source lineage

Company context

Chugai Pharmaceutical Co., Ltd.

TSE:4519

Pharmaceuticals: Major · benchmarked against Pharmaceuticals: Major inside the JPJY constituent company universe.

Active tabFinancial reports

Current readMixed

Last close7,237.00

1M return-5.03%

Open symbol page Watchlist context

OverviewVerdict, thesis map, and valuation setup.FundamentalsDrivers, trajectory, and business quality.Financial reportsStatement tables, sorting, filtering, and acceleration.Ex-ante forecastTarget price, dividend yield, and total return by horizon.FactorsCompany factor exposure, rank, and universe context.Market viewMomentum, catalysts, charts, and symbol packet.AttributionLarge-move causes, residuals, and research backlog.OwnershipSEC 13F holder flow, crowding, and manager changes.PeersPeer heatmap and closest comparables.

Tab scope

Raw financial statements

Financial reports

Source and lookbackStored financial report rows12 report snapshots; latest report Apr 28, 11:27 AM GMT+8.

Sample and caveat28 reported metrics across 4 sections.Use this tab for its stated job; heavier model packets stay on their own tabs.

Traditional statement tables

Financial reports

12 reports · latest Apr 28, 11:27 AM GMT+8

Distinct report rows12

Sections4

Metrics28

Coverage100%

CompanyChugai Pharmaceutical Co., Ltd.

Overview scoring

Fundamental overview

62/100 blended · 93/100 confidence · benchmark Closest peers

Blended fundamental score: Earnings 68/100; Cash flow 64/100; Balance sheet 80/100; Valuation 17/100.

Broad comparison

Cohort scorecard

Coverage-adjusted score with thinner cohorts automatically down-weighted

Cohort scorecard: Closest peers 64/100; Pharmaceuticals: Major 63/100; Health Technology 65/100; JPJY constituent company universe 57/100.

Selected company rank

Rank and percentile

Confidence-adjusted standing inside each cohort

Rank and percentile: Closest peers #2 of 13; Pharmaceuticals: Major #2 of 7; Health Technology #2 of 11; JPJY constituent company universe #30 of 168.

Section scoring matrix

Earnings, cash flow, balance sheet, and valuation

Heatmap score by cohort and statement section

Section scoring matrix: Closest peers Earnings 71/100; Cash flow 67/100; Balance sheet 80/100; Valuation 17/100.

Sort byFilter metrics

Specialist report review

Quant, PM, and risk-manager reads

Deterministic review lanes from stored report metrics

Quant review

Favorable acceleration10/21

Debt / Equity has the largest second-order move at -125.90%. 10 metrics are accelerating favorably and 11 are decelerating.

Fundamental PM review

Growth and cash quality2/5

EPS TTM is 1.73 with -99.34% latest change. The PM lane checks revenue, EPS, cash flow, and margin confirmation together.

Risk manager review

Risk controls stableNo active flags

Debt / Equity is 0.01 with -27.70% latest change. The risk lane checks leverage, liquidity, and cash-yield deterioration.

Indexed report history

Financial report trend chart

First visible report = 100

Financial report trend chart: Total revenue 8B; Revenue quarter 2B; Operating income TTM 4.1B; Operating margin +51.12%.

Second order change

Acceleration chart

Favorable acceleration means the latest move improved versus the prior move

Acceleration chart: Total revenue -103.01%; Revenue quarter -103.35%; Operating income TTM -107.31%; Operating margin -1.72%.

PM / risk lens

Risk and quality radar

Directional score from change and acceleration

Risk and quality radar: Growth 13/100; Cash 41/100; Quality 53/100; Balance 89/100; Valuation 72/100.

Earnings

Metric trend table

10 of 10 metrics shown

Metric	Latest	Change	Acceleration	Trend	Samples
Total revenueRevenue	8B	-99.36%-1.2T	-103.01%-1.3T	decelerating	12
Revenue quarterRevenue	2B	-99.41%-344.3B	-103.35%-357.4B	decelerating	12
Revenue next quarterRevenue	2.2B	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Operating income TTMEarnings	4.1B	-99.35%-623.6B	-107.31%-669.9B	decelerating	12
Operating marginProfitability	+51.12%	+2.44%+1.22 pts	-1.72%-0.78 pts	decelerating	12
EPS TTMEarnings	1.73	-99.34%-261.98	-108.62%-284.36	decelerating	12
EPS next quarterEarnings	0.47	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Gross marginQuality	+71.45%	+0.51%+0.36 pts	-1.81%-1.25 pts	decelerating	12
Net marginQuality	+35.02%	+1.50%+0.52 pts	-3.93%-1.26 pts	decelerating	12
Gross-to-net conversionQuality	+49.01%	+0.99%+0.48 pts	-2.06%-0.96 pts	decelerating	12

Historical statement rows

Earnings report history

12 dated rows

Snapshot date	Total revenue	Revenue quarter	Revenue next quarter	Operating income TTM	Operating margin	EPS TTM	EPS next quarter	Gross margin	Net margin	Gross-to-net conversion
Jul 3, 2023	1.2T	267.4B	—	453.9B	+36.50%	198.72	—	+57.78%	+26.30%	+45.51%
Oct 2, 2023	1.3T	257.9B	—	463.7B	+36.34%	204.65	—	+58.14%	+26.39%	+45.39%
Jan 4, 2024	1.1T	273.8B	—	426B	+38.33%	197.80	—	+62.81%	+29.29%	+46.63%
Apr 1, 2024	1T	236.9B	—	423.9B	+40.92%	198.34	—	+67.67%	+31.50%	+46.55%
Jul 1, 2024	1.1T	315.9B	—	482.5B	+44.49%	215.75	—	+69.46%	+32.74%	+47.13%
Oct 7, 2024	1.1T	315.7B	—	536.3B	+46.94%	235.14	—	+70.48%	+33.87%	+48.06%
Jan 6, 2025	1.2T	302.1B	—	545.1B	+46.56%	235.36	—	+71.01%	+33.09%	+46.60%
Apr 7, 2025	1.2T	288.5B	—	582.4B	+47.65%	249.23	—	+71.01%	+33.56%	+47.26%
Jul 7, 2025	1.2T	290B	—	562.9B	+47.06%	240.29	—	+70.37%	+33.06%	+46.98%
Oct 6, 2025	1.2T	333.2B	—	581.4B	+47.90%	241.33	—	+69.48%	+32.72%	+47.10%
Jan 5, 2026	1.3T	346.3B	—	627.7B	+49.90%	263.71	—	+71.09%	+34.50%	+48.53%
Apr 28, 2026	8B	2B	2.2B	4.1B	+51.12%	1.73	0.47	+71.45%	+35.02%	+49.01%